RespireRx Pharmaceuticals Management
Management criteria checks 4/4
RespireRx Pharmaceuticals' CEO is Arnold Lippa, appointed in Aug 2015, has a tenure of 8.75 years. total yearly compensation is $339.60K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 1.48% of the company’s shares, worth $11.46K. The average tenure of the management team and the board of directors is 9.6 years and 9.7 years respectively.
Key information
Arnold Lippa
Chief executive officer
US$339.6k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 8.8yrs |
| CEO ownership | 1.5% |
| Management average tenure | 9.6yrs |
| Board average tenure | 9.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$2m |
| Jun 30 2023 | n/a | n/a | -US$3m |
| Mar 31 2023 | n/a | n/a | -US$4m |
| Dec 31 2022 | US$340k | US$340k | -US$4m |
| Sep 30 2022 | n/a | n/a | -US$4m |
| Jun 30 2022 | n/a | n/a | -US$4m |
| Mar 31 2022 | n/a | n/a | -US$4m |
| Dec 31 2021 | US$340k | US$340k | -US$4m |
| Sep 30 2021 | n/a | n/a | -US$5m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$6m |
| Dec 31 2020 | US$340k | US$340k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$3m |
| Mar 31 2020 | n/a | n/a | -US$3m |
| Dec 31 2019 | US$340k | US$340k | -US$2m |
| Sep 30 2019 | n/a | n/a | -US$2m |
| Jun 30 2019 | n/a | n/a | -US$2m |
| Mar 31 2019 | n/a | n/a | -US$2m |
| Dec 31 2018 | US$340k | US$340k | -US$3m |
| Sep 30 2018 | n/a | n/a | -US$3m |
| Jun 30 2018 | n/a | n/a | -US$3m |
| Mar 31 2018 | n/a | n/a | -US$4m |
| Dec 31 2017 | US$614k | US$340k | -US$4m |
Compensation vs Market: Arnold's total compensation ($USD339.60K) is below average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Arnold's compensation has been consistent with company performance over the past year.
CEO
Arnold Lippa (76 yo)
8.8yrs
Tenure
US$339,600
Compensation
Dr. Arnold S. Lippa, Ph D., has been an Executive Chairman of RespireRx Pharmaceuticals Inc., since March 22, 2013 and its Chief Scientific Officer since August 19, 2015 and has been its Interim President...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 8.8yrs | US$339.60k | 1.48% $ 11.5k | |
| Senior VP | 11.2yrs | US$321.60k | 1.37% $ 10.6k | |
| Senior Vice President of Research & Development | 9.6yrs | US$199.86k | 0.000080% $ 0.6 | |
| Senior Vice President of Pre-Clinical Product Development | 3.7yrs | no data | 0% $ 0 | |
| Controller | 10.9yrs | no data | 0.27% $ 2.1k |
9.6yrs
Average Tenure
64.5yo
Average Age
Experienced Management: RSPI's management team is seasoned and experienced (9.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 11.2yrs | US$339.60k | 1.48% $ 11.5k | |
| Senior VP | 11.2yrs | US$321.60k | 1.37% $ 10.6k | |
| Independent Director | 1.2yrs | no data | no data | |
| Chairman of Scientific Advisory Board | 9.7yrs | no data | no data | |
| Director | less than a year | no data | no data |
9.7yrs
Average Tenure
75yo
Average Age
Experienced Board: RSPI's board of directors are considered experienced (9.7 years average tenure).